{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"}]}],"title":"Baseline Score 0, Post-Baseline Score 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"52"}]}],"title":"Baseline Score 0, Post-Baseline Score 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"23"}]}],"title":"Baseline Score 0, Post-Baseline Score 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}],"title":"Baseline Score 0, Post-Baseline Score 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"Baseline Score 1, Post-Baseline Score 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"104"}]}],"title":"Baseline Score 1, Post-Baseline Score 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"57"}]}],"title":"Baseline Score 1, Post-Baseline Score 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"9"}]}],"title":"Baseline Score 1, Post-Baseline Score 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}]}],"title":"Baseline Score 1, Post-Baseline Score 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"8"}]}],"title":"Baseline Score 2, Post-Baseline Score 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"35"}]}],"title":"Baseline Score 2, Post-Baseline Score 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"}]}],"title":"Baseline Score 2, Post-Baseline Score 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"title":"Baseline Score 2, Post-Baseline Score 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"344"},{"groupId":"OG001","value":"340"}],"units":"Participants"}],"description":"Eastern Cooperative Oncology Group (ECOG) scale score ranged from 0 to 5, where 0 indicated normal activity and 5 indicated death. The data is reported for those categories where at least 1 participant had worst post-baseline value for each ECOG score.","groups":[{"description":"Participants who were randomly assigned to receive placebo matching capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) for the first 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib matching placebo capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).","id":"OG000","title":"Placebo + LenDex"},{"description":"Participants who were randomly assigned to receive Ixazomib 4.0 mg capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) for the first 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).","id":"OG001","title":"Ixazomib + LenDex"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population is defined as all participants who receive at least 1 dose of any study drug. Overall number of participants analyzed indicates number of participants available for analysis.","reportingStatus":"POSTED","timeFrame":"Up to approximately 9 years","title":"Number of Participants With Shifts From Baseline to Worst Value in Eastern Cooperative Oncology Group (ECOG) Performance Score","type":"SECONDARY","unitOfMeasure":"Participants"}